IN2014MN02512A - - Google Patents
Info
- Publication number
- IN2014MN02512A IN2014MN02512A IN2512MUN2014A IN2014MN02512A IN 2014MN02512 A IN2014MN02512 A IN 2014MN02512A IN 2512MUN2014 A IN2512MUN2014 A IN 2512MUN2014A IN 2014MN02512 A IN2014MN02512 A IN 2014MN02512A
- Authority
- IN
- India
- Prior art keywords
- diseases
- substituted
- active ingredient
- arteriosclerosis
- agent
- Prior art date
Links
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 2
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 201000009101 diabetic angiopathy Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012134431 | 2012-06-14 | ||
| PCT/JP2013/066306 WO2013187462A1 (ja) | 2012-06-14 | 2013-06-13 | ピペリジニルピラゾロピリジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02512A true IN2014MN02512A (de) | 2015-07-17 |
Family
ID=49758280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2512MUN2014 IN2014MN02512A (de) | 2012-06-14 | 2013-06-13 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9150575B2 (de) |
| EP (1) | EP2862861B1 (de) |
| JP (1) | JPWO2013187462A1 (de) |
| KR (1) | KR20150021036A (de) |
| CN (1) | CN104781257A (de) |
| BR (1) | BR112014030954A2 (de) |
| CA (1) | CA2876382A1 (de) |
| ES (1) | ES2563861T3 (de) |
| HK (1) | HK1207375A1 (de) |
| IN (1) | IN2014MN02512A (de) |
| RU (1) | RU2015100942A (de) |
| TW (1) | TW201402572A (de) |
| WO (1) | WO2013187462A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110179795A (zh) | 2013-03-15 | 2019-08-30 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途 |
| WO2015050148A1 (ja) * | 2013-10-04 | 2015-04-09 | 第一三共株式会社 | ３－アリールピラゾロピリジン誘導体 |
| WO2015076353A1 (ja) * | 2013-11-25 | 2015-05-28 | 第一三共株式会社 | ３－アルキルピラゾロピリジン誘導体 |
| WO2015087996A1 (ja) * | 2013-12-13 | 2015-06-18 | 第一三共株式会社 | イミダゾピリジン誘導体 |
| EP3081566B1 (de) | 2013-12-13 | 2018-03-07 | Daiichi Sankyo Company, Limited | 5-hydroxy-4-(trifluormethyl)pyrazolopyridinderivat |
| WO2015087995A1 (ja) * | 2013-12-13 | 2015-06-18 | 第一三共株式会社 | シクロアルキル又はヘテロシクリルピラゾロピリジン誘導体 |
| CN103694220A (zh) * | 2013-12-30 | 2014-04-02 | 张磊 | 新型吡唑-3-甲酸酯及合成方法 |
| WO2015111545A1 (ja) * | 2014-01-21 | 2015-07-30 | 第一三共株式会社 | 縮合ピラゾール誘導体 |
| US10189810B2 (en) | 2014-09-17 | 2019-01-29 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| CN107405333A (zh) | 2015-02-27 | 2017-11-28 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
| TWI713534B (zh) * | 2015-06-11 | 2020-12-21 | 日商第一三共股份有限公司 | 5-羥基-4-(三氟甲基)吡唑并吡啶衍生物之結晶及其用途 |
| CN106916143B (zh) * | 2017-03-14 | 2019-09-27 | 哈尔滨医科大学 | 一种预防和治疗冠心病的药物及其应用 |
| EP3777859A4 (de) | 2018-03-30 | 2021-11-24 | Daiichi Sankyo Company, Limited | Therapeutikum für lcat-mangel |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| US12606558B2 (en) | 2020-04-09 | 2026-04-21 | Disarm Therapeutics, Inc. | Condensed pyrazole derivatives as inhibitors of SARM1 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005019200A2 (en) | 2003-08-14 | 2005-03-03 | Icos Corporation | Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof |
| WO2005105092A2 (en) | 2004-04-28 | 2005-11-10 | Merck & Co., Inc. | 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity |
| SE0403171D0 (sv) | 2004-12-23 | 2004-12-23 | Astrazeneca Ab | New compounds |
| JPWO2007111323A1 (ja) | 2006-03-27 | 2009-08-13 | 東レ株式会社 | ウレイド誘導体およびその医薬用途 |
| EP2452683A3 (de) | 2006-06-26 | 2012-08-22 | Amgen Inc. | Verfahren zur Behandlung von Atherosklerose |
| BRPI0720607A2 (pt) | 2006-12-21 | 2014-04-08 | Lilly Co Eli | Compostos de imidazolidinonil aminopirimidina |
| EP3088397B1 (de) | 2007-04-11 | 2019-04-10 | Canbas Co. Ltd. | Verbindungen, die den g2-checkpoint des zellzyklus stilllegen und dadurch eine antikrebswirkung aufweisen |
| KR20100059919A (ko) | 2007-09-24 | 2010-06-04 | 코멘티스, 인코포레이티드 | 치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물 |
| EP2080758A3 (de) | 2007-11-29 | 2009-08-26 | Bayer CropScience AG | Halogen substituierte delta-1-Pyrroline |
| EP2236494B1 (de) | 2007-12-26 | 2016-08-31 | Msd K.K. | Sulfonyl-substituierte 6-gliedrige ringderivate |
| US20110053933A1 (en) | 2008-03-26 | 2011-03-03 | Daiichi Sankyo Company, Limited | Hydroxyquinoxalinecarboxamide derivative |
| GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
| US8394834B2 (en) | 2009-08-25 | 2013-03-12 | Hoffman-La Roche Inc. | Pyrrolidines as NK3 receptor antagonists |
| JP2013506669A (ja) | 2009-09-30 | 2013-02-28 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｅｒｋ阻害剤である新規化合物 |
| FR2951172B1 (fr) | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
| JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| ES2530345T3 (es) * | 2010-09-02 | 2015-03-02 | Merck Patent Gmbh | Derivados de pirazolopiridinona como antagonistas del receptor del LPA |
-
2013
- 2013-06-13 IN IN2512MUN2014 patent/IN2014MN02512A/en unknown
- 2013-06-13 KR KR20147034506A patent/KR20150021036A/ko not_active Withdrawn
- 2013-06-13 CN CN201380043286.5A patent/CN104781257A/zh active Pending
- 2013-06-13 ES ES13804804.6T patent/ES2563861T3/es active Active
- 2013-06-13 EP EP13804804.6A patent/EP2862861B1/de not_active Not-in-force
- 2013-06-13 CA CA2876382A patent/CA2876382A1/en not_active Abandoned
- 2013-06-13 HK HK15108048.8A patent/HK1207375A1/en unknown
- 2013-06-13 WO PCT/JP2013/066306 patent/WO2013187462A1/ja not_active Ceased
- 2013-06-13 JP JP2014521397A patent/JPWO2013187462A1/ja active Pending
- 2013-06-13 BR BR112014030954A patent/BR112014030954A2/pt not_active IP Right Cessation
- 2013-06-13 RU RU2015100942A patent/RU2015100942A/ru unknown
- 2013-06-14 TW TW102121023A patent/TW201402572A/zh unknown
-
2014
- 2014-12-10 US US14/566,460 patent/US9150575B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015100942A (ru) | 2016-08-10 |
| TW201402572A (zh) | 2014-01-16 |
| CN104781257A (zh) | 2015-07-15 |
| US9150575B2 (en) | 2015-10-06 |
| EP2862861A1 (de) | 2015-04-22 |
| ES2563861T3 (es) | 2016-03-16 |
| BR112014030954A2 (pt) | 2017-06-27 |
| EP2862861B1 (de) | 2016-01-06 |
| KR20150021036A (ko) | 2015-02-27 |
| CA2876382A1 (en) | 2013-12-19 |
| WO2013187462A1 (ja) | 2013-12-19 |
| EP2862861A4 (de) | 2015-04-22 |
| JPWO2013187462A1 (ja) | 2016-02-08 |
| HK1207375A1 (en) | 2016-01-29 |
| US20150152102A1 (en) | 2015-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02512A (de) | ||
| PH12016501129A1 (en) | 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative | |
| PH12012501473A1 (en) | Cycloalkyl-substituted imidazole derivative | |
| JOP20210064A1 (ar) | عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة | |
| EA201290632A1 (ru) | Производные бетулина | |
| WO2013019561A8 (en) | Nuclear transport modulators and uses thereof | |
| BR112012019672A2 (pt) | pirrolidina-2-carboxamidas substituídas. | |
| JO3387B1 (ar) | مشتقات بيتولين | |
| HUE054473T2 (hu) | Eljárás HIV-integráz inhibitor hatású vegyületek elõállítására | |
| MY170326A (en) | Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors | |
| PE20150332A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de cinasa | |
| WO2010122980A8 (ja) | 新規甲状腺ホルモンβ受容体作動薬 | |
| WO2011012816A3 (fr) | Formulation pharmaceutique | |
| PH12013501750A1 (en) | Guanidine compound | |
| WO2013020024A3 (en) | Maleimide compounds and methods of treatment | |
| MX2015003594A (es) | Agente terapeutico o profilactico para sindrome de lisis tumoral. | |
| PH12018500261A1 (en) | Azole benzene derivative | |
| NZ603465A (en) | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient | |
| WO2014172188A3 (en) | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors | |
| TN2012000092A1 (en) | Therapeutic agent for mood disorders | |
| IN2014CN04449A (de) | ||
| WO2014036502A3 (en) | Tetracycline compounds | |
| IN2014DN05972A (de) | ||
| WO2010132670A3 (en) | Pentacycline compounds | |
| WO2013062332A3 (ko) | 시링가레시놀을 포함하는 혈관 노화 억제용 조성물 |